Establishment of a Bovine Herpesvirus 4 based vector expressing a secreted form of the Bovine Viral Diarrhoea Virus structural glycoprotein E2 for immunization purposes-2

<p><b>Copyright information:</b></p><p>Taken from "Establishment of a Bovine Herpesvirus 4 based vector expressing a secreted form of the Bovine Viral Diarrhoea Virus structural glycoprotein E2 for immunization purposes"</p><p>http://www.biomedcentral.com/1472-6750/7/68</p><p>BMC Biotechnology 2007;7():68-68.</p><p>Published online 18 Oct 2007</p><p>PMCID:PMC2048506.</p><p></p> different types of infection (persistent, permissive and unpermissive infection)

Establishment of a Bovine Herpesvirus 4 based vector expressing a secreted form of the Bovine Viral Diarrhoea Virus structural glycoprotein E2 for immunization purposes-3

<p><b>Copyright information:</b></p><p>Taken from "Establishment of a Bovine Herpesvirus 4 based vector expressing a secreted form of the Bovine Viral Diarrhoea Virus structural glycoprotein E2 for immunization purposes"</p><p>http://www.biomedcentral.com/1472-6750/7/68</p><p>BMC Biotechnology 2007;7():68-68.</p><p>Published online 18 Oct 2007</p><p>PMCID:PMC2048506.</p><p></p>and destroy the cell monolayer. (b) The quantitative assay performed in a 96-multiwell plate where 4 sera (1, 2, 3, and 4) containing neutralizing antibody against BVDV were tested at different dilutions in the presence of gE2-14 (+Sera +E2) and in the absence of gE2-14 (+Sera -E2). Control virus was established in the absence of sera and presence of gE2-14 and in the absence of sera and gE2-14. Crystal violet staining allows macroscopic evaluation of the integrity or the destruction of the cell monolayer. (c) Bar graph showing the quantification of serum neutralization made on the basis of three different experiments (** = < 0.001). Results are expressed as the log2 of the highest dilution of the serum that inhibited the development of virus-induced cytopathic effect in cell culture

Establishment of a Bovine Herpesvirus 4 based vector expressing a secreted form of the Bovine Viral Diarrhoea Virus structural glycoprotein E2 for immunization purposes-5

<p><b>Copyright information:</b></p><p>Taken from "Establishment of a Bovine Herpesvirus 4 based vector expressing a secreted form of the Bovine Viral Diarrhoea Virus structural glycoprotein E2 for immunization purposes"</p><p>http://www.biomedcentral.com/1472-6750/7/68</p><p>BMC Biotechnology 2007;7():68-68.</p><p>Published online 18 Oct 2007</p><p>PMCID:PMC2048506.</p><p></p>k box), the IgK signal peptide (red box) in frame with the E2 ORF and 14 hydrophilic extra amino acids peptide (14aa, green box) and the bovine growth hormone polyadenylation signal (PA, white box). b) Diagram (not to scale) showing the pCMV-IgKE2-23 vector along with the sequence and the predicted amino-acid product, containing: the CMV enhancer promoter (black box), the IgK signal peptide (red box) in frame with the E2 ORF and 23 hydrophobic extra amino acids peptide (23aa, green box) and the bovine growth hormone polyadenylation signal (PA, white box). c) Hydrophilicity plot of the 14 aa and 23 aa (in d) peptides with the calculated net charge, iso-electric point and the average hydrophilicity. e) Western immunoblotting of cell extracts and supernatant of cells transfected with pIgKE2-14 and pIgKE2-23

Establishment of a Bovine Herpesvirus 4 based vector expressing a secreted form of the Bovine Viral Diarrhoea Virus structural glycoprotein E2 for immunization purposes-0

<p><b>Copyright information:</b></p><p>Taken from "Establishment of a Bovine Herpesvirus 4 based vector expressing a secreted form of the Bovine Viral Diarrhoea Virus structural glycoprotein E2 for immunization purposes"</p><p>http://www.biomedcentral.com/1472-6750/7/68</p><p>BMC Biotechnology 2007;7():68-68.</p><p>Published online 18 Oct 2007</p><p>PMCID:PMC2048506.</p><p></p>k box), the IgK signal peptide (red box) in frame with the E2 ORF and 14 hydrophilic extra amino acids peptide (14aa, green box) and the bovine growth hormone polyadenylation signal (PA, white box). b) Diagram (not to scale) showing the pCMV-IgKE2-23 vector along with the sequence and the predicted amino-acid product, containing: the CMV enhancer promoter (black box), the IgK signal peptide (red box) in frame with the E2 ORF and 23 hydrophobic extra amino acids peptide (23aa, green box) and the bovine growth hormone polyadenylation signal (PA, white box). c) Hydrophilicity plot of the 14 aa and 23 aa (in d) peptides with the calculated net charge, iso-electric point and the average hydrophilicity. e) Western immunoblotting of cell extracts and supernatant of cells transfected with pIgKE2-14 and pIgKE2-23

Additional file 1: of Diagnosis, treatment and prevention of pediatric obesity: consensus position statement of the Italian Society for Pediatric Endocrinology and Diabetology and the Italian Society of Pediatrics

Level of evidence and grade of recommendations according to the National Guidelines System [4]. (DOCX 15 kb